Cerrahpaşa Medical Journal
ORIGINAL ARTICLE

Genetic Features and TP53 Mutations in Chronic Lymphocytic Leukemia

1.

İstanbul Medeniyet Üniversitesi, Göztepe Eğitim ve Araştırma Hastanesi, Erişkin Hematoloji Kliniği, İstanbul, Türkiye

2.

İstanbul Üniversitesi-Cerrahpaşa, Cerrahpaşa Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Hematoloji Bilim Dalı, İstanbul, Türkiye

3.

İstanbul Üniversitesi, Aziz Sancar Deneysel Tıp Araştırma Enstitüsü, Genetik Ana Bilim Dalı, İstanbul, Türkiye

Cerrahpasa Med J 2021; 45: 221-226
DOI: 10.5152/cjm.2021.21021
Read: 247 Downloads: 104 Published: 23 August 2021

Objective: In this study, we aimed to evaluate the incidence and type of tumor protein 53 mutations and compare this with 17p deletion and other prognostic factors in 50 outpatient patients who were diagnosed with chronic lymphocytic leukemia between 2001 and 2013 in our hematology outpatient clinic.

Methods: In the study, 10 cc of blood was collected from patients and variations in the 4-11 exons of the tumor protein 53 gene in the cDNAs were determined by polymerase chain reaction and Sanger sequence analysis methods. Demographic data as age, sex, time of diagnosis, time interval between diagnosis and treatment, disease stage, 17p deletion status, zeta-associated-protein kinase 70 and CD38 positivity were obtained retrospectively from outpatient files.

Results: Twenty-eight patients (56%) were male. Age interval was between 36 and 68 years. 17p deletion analyzed by fluorescence in situ hybridization was positive in 7 patients (14%) and negative in 43 patients (86%). Tumor protein 53 mutations could be analyzed in 17 patients; 5 patients were wild type, and all of the remaining 12 patients had a cytosine (C) to guaine base (G) alteration at position 215. This alteration was considered as a single nucleotide polymorphism. In 9 of the patients with mutations in the tumor protein 53 gene, 17p deletion was negative.

Conclusion: Current treatment guidelines recommend screening for 17p deletion in chronic lymphocytic leukemia patients, but do not include screening for tumor protein 53 mutations. In our study group, tumor protein 53 gene polymorphism which has been associated with poor prognosis and drug resistance in the literature was detected in 12 (70.5%) of 17 patients. Since 9 of the patients (75%) with tumor protein 53 gene polymorphism were found to be 17p deletion negative, in addition to 17p deletion, the analysis of tumor protein 53 gene mutations can be recommended, at least before planning the treatment or before changing the treatment regimen in poor responsive patients.

Cite this article as: Erdoğan Özünal I, Elverdi T, Salihoğlu A, et al. Genetic features and TP53 mutations in chronic lymphocytic leukemia. Cerrahpaşa Med J. 2021;45(3):221-226.

Files
EISSN 2687-1904